DHL Group acquires CRYOPDP from Cryoport to strengthen "DHL Health Logistics"
DHL Group has announced the acquisition of CRYOPDP from Cryoport, Inc. (NASDAQ: CYRX), marking a significant expansion in specialized pharma logistics. CRYOPDP, operating in 15 countries and handling over 600,000 shipments annually across 135 countries, specializes in clinical trials, biopharma, and cell & gene therapy logistics.
The acquisition strengthens DHL's Life Sciences and Healthcare business, which generated over EUR 5 billion in global revenue in 2024. As part of the deal, DHL and Cryoport will form a strategic partnership to enhance their supply chain service offerings in the global life sciences sector.
This strategic move aligns with DHL Group's Strategy 2030, focusing on temperature-controlled networks and specialty courier coverage. The partnership aims to leverage DHL's global logistics capabilities with Cryoport's specialized solutions, particularly expanding their reach in APAC and EMEA regions.
DHL Group ha annunciato l'acquisizione di CRYOPDP da Cryoport, Inc. (NASDAQ: CYRX), segnando un'importante espansione nella logistica farmaceutica specializzata. CRYOPDP, operante in 15 paesi e gestendo oltre 600.000 spedizioni annuali in 135 paesi, è specializzata nella logistica per studi clinici, biopharma e terapie cellulari e geniche.
L'acquisizione rafforza il business Life Sciences e Healthcare di DHL, che ha generato oltre 5 miliardi di EUR di fatturato globale nel 2024. Come parte dell'accordo, DHL e Cryoport formeranno una partnership strategica per migliorare le loro offerte di servizi nella catena di approvvigionamento nel settore globale delle scienze della vita.
Questa mossa strategica si allinea con la Strategia 2030 del DHL Group, concentrandosi su reti a temperatura controllata e copertura di corrieri specializzati. La partnership mira a sfruttare le capacità logistiche globali di DHL con le soluzioni specializzate di Cryoport, in particolare espandendo la loro portata nelle regioni APAC ed EMEA.
DHL Group ha anunciado la adquisición de CRYOPDP de Cryoport, Inc. (NASDAQ: CYRX), marcando una expansión significativa en la logística farmacéutica especializada. CRYOPDP, que opera en 15 países y maneja más de 600,000 envíos anuales en 135 países, se especializa en ensayos clínicos, biopharma y logística de terapias celulares y génicas.
La adquisición refuerza el negocio de Ciencias de la Vida y Salud de DHL, que generó más de 5 mil millones de EUR en ingresos globales en 2024. Como parte del acuerdo, DHL y Cryoport formarán una asociación estratégica para mejorar sus ofertas de servicios de cadena de suministro en el sector global de ciencias de la vida.
Este movimiento estratégico se alinea con la Estrategia 2030 del DHL Group, enfocándose en redes controladas por temperatura y cobertura de mensajería especializada. La asociación tiene como objetivo aprovechar las capacidades logísticas globales de DHL junto con las soluciones especializadas de Cryoport, expandiendo particularmente su alcance en las regiones APAC y EMEA.
DHL 그룹은 Cryoport, Inc. (NASDAQ: CYRX)로부터 CRYOPDP를 인수했다고 발표하며, 전문 제약 물류 분야에서 중요한 확장을 의미합니다. CRYOPDP는 15개국에서 운영되며 135개국에서 연간 600,000건 이상의 배송을 처리하며, 임상 시험, 생명공학 및 세포 및 유전자 치료 물류를 전문으로 합니다.
이번 인수는 DHL의 생명 과학 및 의료 사업을 강화하며, 2024년에는 전 세계에서 50억 유로 이상의 수익을 창출했습니다. 이번 거래의 일환으로 DHL과 Cryoport는 글로벌 생명 과학 부문에서 공급망 서비스 제공을 강화하기 위한 전략적 파트너십을 형성할 것입니다.
이 전략적 움직임은 DHL 그룹의 2030 전략과 일치하며, 온도 조절 네트워크와 전문 운송 서비스에 초점을 맞추고 있습니다. 이 파트너십은 DHL의 글로벌 물류 역량과 Cryoport의 전문 솔루션을 결합하여 특히 APAC 및 EMEA 지역에서의 범위를 확장하는 것을 목표로 합니다.
DHL Group a annoncé l'acquisition de CRYOPDP de Cryoport, Inc. (NASDAQ: CYRX), marquant une expansion significative dans la logistique pharmaceutique spécialisée. CRYOPDP, qui opère dans 15 pays et gère plus de 600 000 expéditions annuelles dans 135 pays, se spécialise dans les essais cliniques, la biopharma et la logistique des thérapies cellulaires et géniques.
L'acquisition renforce l'activité Sciences de la Vie et Santé de DHL, qui a généré plus de 5 milliards d'EUR de revenus mondiaux en 2024. Dans le cadre de l'accord, DHL et Cryoport établiront un partenariat stratégique pour améliorer leurs offres de services de chaîne d'approvisionnement dans le secteur mondial des sciences de la vie.
Ce mouvement stratégique s'aligne avec la Stratégie 2030 du DHL Group, axée sur des réseaux à température contrôlée et une couverture de messagerie spécialisée. Le partenariat vise à tirer parti des capacités logistiques mondiales de DHL avec les solutions spécialisées de Cryoport, en particulier pour étendre leur portée dans les régions APAC et EMEA.
DHL Group hat die Übernahme von CRYOPDP von Cryoport, Inc. (NASDAQ: CYRX) bekannt gegeben, was eine bedeutende Erweiterung im Bereich der spezialisierten Pharma-Logistik darstellt. CRYOPDP ist in 15 Ländern tätig und bearbeitet jährlich über 600.000 Sendungen in 135 Ländern, wobei es sich auf klinische Studien, Biopharma und Logistik für Zell- und Gentherapien spezialisiert hat.
Die Übernahme stärkt das Geschäft von DHL in den Bereichen Life Sciences und Healthcare, das im Jahr 2024 über 5 Milliarden EUR an globalen Einnahmen erzielte. Im Rahmen des Deals werden DHL und Cryoport eine strategische Partnerschaft bilden, um ihre Dienstleistungen in der globalen Lieferkette im Bereich der Lebenswissenschaften zu verbessern.
Dieser strategische Schritt steht im Einklang mit der Strategie 2030 der DHL Group, die sich auf temperaturkontrollierte Netzwerke und spezialisierte Kurierdienste konzentriert. Die Partnerschaft zielt darauf ab, die globalen Logistikfähigkeiten von DHL mit den spezialisierten Lösungen von Cryoport zu kombinieren, insbesondere um ihre Reichweite in den Regionen APAC und EMEA auszubauen.
- Acquisition provides access to CRYOPDP's network of 600,000+ annual shipments across 135 countries
- Strengthens DHL's EUR 5 billion Life Sciences and Healthcare business
- Strategic partnership enables market expansion in APAC and EMEA regions
- Expected cost savings through integration with DHL Express and Global Forwarding capabilities
- Subject to regulatory approvals which could delay completion
- Integration challenges of merging CRYOPDP's operations with DHL's existing infrastructure
Insights
Cryoport's divestiture of CRYOPDP to DHL Group represents a strategic realignment that could strengthen Cryoport's financial position while maintaining access to critical logistics capabilities through the announced partnership. While financial terms weren't disclosed, this transaction allows Cryoport to monetize a subsidiary while simultaneously securing a strategic relationship with a global logistics powerhouse.
The deal appears designed to let Cryoport focus on its core cryogenic technologies and solutions while leveraging DHL's established global infrastructure to expand market reach. For a company with a
Particularly significant is the partnership aspect, which suggests Cryoport retains strategic access to the capabilities it's selling. This structure indicates the relationship is mutually beneficial rather than purely transactional, potentially creating an improved competitive position for both entities in the specialized life sciences logistics market.
For investors, this represents a calculated pivot - Cryoport trading direct operational control of CRYOPDP for focused execution, potential balance sheet improvement, and strategic alignment with a
This transaction significantly reshapes the competitive landscape in specialized healthcare logistics. By acquiring CRYOPDP, DHL gains specialized capabilities in temperature-sensitive shipments for clinical trials and cell & gene therapies - areas requiring precision beyond conventional pharmaceutical logistics. The partnership structure allows Cryoport to simultaneously divest an asset while securing preferred access to DHL's global network.
The strategic implications are substantial. With shipping volumes exceeding 600,000 shipments annually across 135 countries, CRYOPDP provides DHL immediate scale in high-value biopharmaceutical logistics. For Cryoport, the deal appears to represent operational streamlining while maintaining market access through partnership rather than direct ownership.
This arrangement creates a specialized ecosystem where Cryoport can focus on technology development while leveraging DHL's logistics infrastructure - particularly valuable as cell and gene therapies scale commercially, requiring increasingly sophisticated global distribution solutions. The partnership potentially accelerates both companies' market penetration while reducing redundant infrastructure investments.
The timing aligns with broader industry trends toward consolidation in specialized logistics as biologic therapies grow increasingly complex. By partnering with DHL, Cryoport positions itself to capture growth in emerging markets without capital-intensive direct expansion. For Cryoport shareholders, this represents a potential strategic win through reduced operational complexity while maintaining market participation through what appears to be a high-value partnership with the world's leading logistics provider.
- DHL to acquire
100% of CRYOPDP, a leading specialty courier providing logistics services for clinical trials, biopharma, and cell & gene therapies. This acquisition enhances DHL's capabilities in specialty pharma logistics and supports Group's 2030 strategy to become a leader in life science and healthcare logistics. - DHL and Cryoport form strategic partnership to strengthen their respective supply chain services offerings for the global life sciences and healthcare sector.
BONN,
DHL Group already has an established Life Sciences and Healthcare business, contributing over
Going forward, DHL Supply Chain will further build the potential of its Pharma Specialized Network solution by leveraging the specialty courier expertise of newly acquired CRYOPDP and the global air capabilities of DHL Express and DHL Global Forwarding.
The strategic partnership with Cryoport will bring together DHL's global health logistics capabilities with Cryoport's industry-leading expertise in providing specialized solutions in a fast growing life science and healthcare market segment. It also deepens DHL's relationship with all the Cryoport business units with respect to specialized pharma.
Oscar de Bok, CEO of DHL Supply Chain, stated, "The acquisition of CRYOPDP is a pivotal move for our supply chain business as we aim to expand our Pharma Specialized Network to meet the evolving needs of clinical trials, biopharma and cell & gene therapies, in addition to further increasing our footprint in the conventional pharma and life science healthcare segment. The acquisition of CRYOPDP and the extended partnership with Cryoport Inc. will enable us to deliver integrated end-to-end solutions, enhancing our service capabilities ."
Jerrell Shelton, CEO of Cryoport, commented "We are indeed pleased to build on our trusted relationship with the DHL Group. Working together we will bring an enhanced set of supply chain solutions to meet companies' and patients' critical supply chain needs. This strategic partnership taps into the strong expertise of DHL's Supply Chain and CRYOPDP, presenting a substantial opportunity for Cryoport to further expand its reach to global growth markets such as
The acquisition aligns with DHL Group's Strategy 2030, which emphasizes the importance of temperature-controlled networks, first and last mile specialty courier coverage and integrated solutions. CRYOPDP's capabilities will be instrumental in achieving these objectives and help position DHL as a leader in providing comprehensive solutions for the pharma industry. This strategic move is also expected to yield cost savings and improve overall service levels, especially leveraging DHL Express and DHL Global Forwarding air capabilities, ultimately enhancing DHL's footprint in the high-value advanced pharma sector.
For Cryoport, the partnership with DHL will enable it to better execute its business in EMEA and APAC with a stronger focus on its core business in these regions, creating even greater opportunities to offer highly targeted, top-tier services in answering market demand for its services and products.
The deal and the outlined partnership are subject to regulatory approvals.
On the internet: group.dhl.com/press
Follow us at: twitter.com/DHLglobal
DHL – The logistics company for the world
DHL is the leading global brand in the logistics industry. Our DHL divisions offer an unrivalled portfolio of logistics services ranging from national and international parcel delivery, e-commerce shipping and fulfillment solutions, international express, road, air and ocean transport to industrial supply chain management. With about 395,000 employees in more than 220 countries and territories worldwide, DHL connects people and businesses securely and reliably, enabling global sustainable trade flows. With specialized solutions for growth markets and industries including technology, life sciences and healthcare, engineering, manufacturing & energy, auto-mobility and retail, DHL is decisively positioned as "The logistics company for the world".
DHL is part of DHL Group. The Group generated revenues of more than
About Cryoport, Inc.
Cryoport, Inc. (Nasdaq: CYRX), is a global leader in supply chain solutions for the Life Sciences with an emphasis on cell & gene therapies. Cryoport enables manufacturers, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers to carry out their respective business with products and services that are designed to derisk services and provide certainty. We provide a broad array of supply chain solutions for the life sciences industry. Through our platform of critical products and solutions including advanced temperature-controlled packaging, informatics, specialized bio-logistics services, bio-storage, bio-services, and cryogenic systems, we are "Enabling the Future of Medicine™" worldwide, through our innovative systems, compliant procedures, and agile approach to superior supply chain management.
Our corporate headquarters, located in
For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at www.twitter.com/cryoport for live updates.
Forward-Looking Statements
Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to Cryoport's expectations about future benefits of the sale of CRYOPDP and the strategic collaboration with DHL, including the potential impact on future revenue and revenue streams. It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks. Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/dhl-group-acquires-cryopdp-from-cryoport-to-strengthen-dhl-health-logistics-302415637.html
SOURCE Cryoport, Inc.
FAQ
What is the strategic significance of DHL's acquisition of CRYOPDP from Cryoport (CYRX)?
How many shipments does CRYOPDP handle annually and what is its global reach?
What are the key benefits of the strategic partnership between DHL and Cryoport (CYRX)?
How does this acquisition align with DHL's Strategy 2030?
